Samuel Kintz Sells 12,500 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) CEO Samuel Kintz sold 12,500 shares of the stock in a transaction dated Thursday, July 17th. The shares were sold at an average price of $22.52, for a total transaction of $281,500.00. Following the completion of the transaction, the chief executive officer directly owned 940,392 shares in the company, valued at approximately $21,177,627.84. This represents a 1.31% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Samuel Kintz also recently made the following trade(s):

• On Tuesday, June 17th, Samuel Kintz sold 12,500 shares of Enliven Therapeutics stock. The shares were sold at an average price of $22.18, for a total transaction of $277,250.00.
• On Tuesday, June 3rd, Samuel Kintz sold 7,500 shares of Enliven Therapeutics stock. The shares were sold at an average price of $20.05, for a total transaction of $150,375.00.
• On Monday, May 19th, Samuel Kintz sold 5,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $16.49, for a total transaction of $82,450.00.
• On Thursday, May 1st, Samuel Kintz sold 5,330 shares of Enliven Therapeutics stock. The stock was sold at an average price of $20.08, for a total transaction of $107,026.40.

Enliven Therapeutics Stock Down 1.8%

Shares of ELVN stock traded down $0.40 during trading hours on Thursday, hitting $21.95. 222,821 shares of the company's stock traded hands, compared to its average volume of 509,380. The stock's 50 day simple moving average is $20.32 and its 200 day simple moving average is $20.24. The stock has a market cap of $1.08 billion, a PE ratio of -11.43 and a beta of 0.83. Enliven Therapeutics, Inc. has a 12 month low of $13.30 and a 12 month high of $30.03.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.06). As a group, equities research analysts expect that Enliven Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on ELVN. The Goldman Sachs Group began coverage on shares of Enliven Therapeutics in a research report on Monday, June 16th. They set a "buy" rating and a $37.00 target price on the stock. HC Wainwright increased their target price on shares of Enliven Therapeutics from $40.00 to $48.00 and gave the stock a "buy" rating in a research report on Wednesday, July 2nd. Jones Trading decreased their target price on shares of Enliven Therapeutics from $36.00 to $27.00 and set a "buy" rating on the stock in a research report on Friday, May 16th. Finally, Robert W. Baird increased their target price on shares of Enliven Therapeutics from $40.00 to $52.00 and gave the stock an "outperform" rating in a research report on Monday, June 16th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average target price of $41.20.

Hedge Funds Weigh In On Enliven Therapeutics

Hedge funds have recently bought and sold shares of the company. Tower Research Capital LLC TRC raised its stake in Enliven Therapeutics by 230.2% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,598 shares of the company's stock worth $36,000 after buying an additional 1,114 shares during the last quarter. GAMMA Investing LLC raised its stake in Enliven Therapeutics by 3,058.1% during the first quarter. GAMMA Investing LLC now owns 2,716 shares of the company's stock worth $53,000 after buying an additional 2,630 shares during the last quarter. Quantbot Technologies LP bought a new position in Enliven Therapeutics during the first quarter worth $60,000. KLP Kapitalforvaltning AS acquired a new stake in Enliven Therapeutics in the fourth quarter worth $97,000. Finally, BNP Paribas Financial Markets acquired a new stake in Enliven Therapeutics in the fourth quarter worth $112,000. Institutional investors own 95.08% of the company's stock.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.